SpyGlass Pharma, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 |
|---|---|---|
| Operating Activities | ||
| Net Income | $-39.9M | $-29.2M |
| Depreciation & Amortization | — | — |
| Depreciation | $612.0K | $271.0K |
| Amortization | — | — |
| Stock-Based Compensation | $2.8M | $1.5M |
| Net Cash from Operating Activities | $-32.7M | $-22.0M |
| Investing Activities | ||
| Capital Expenditures | $789.0K | $2.0M |
| Business Acquisitions | — | — |
| Net Cash from Investing Activities | $-11.8M | $22.3M |
| Financing Activities | ||
| Dividends Paid | — | — |
| Stock Repurchases | $1.5M | $0 |
| Net Cash from Financing Activities | $124.6M | $185.0K |
| Net Change in Cash | $80.1M | $419.0K |
| Free Cash Flow | $-33.5M | $-24.0M |